The mean prostate cancer-specific progression-free survival times for TLR9-negative and TLR9-positive tumors were 147 (95% CI, 138–161) and 116 (95% CI, 105–128) months, respectively (P=0.009). The gene discussed is TLR9; the disease is prostate carcinoma.